Core Viewpoint - Soleno Therapeutics, Inc. is facing a securities fraud lawsuit due to allegations of misleading statements and undisclosed risks related to its drug DCCR, which has resulted in significant stock price declines and investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2026, with a deadline to file a lead plaintiff motion by May 5, 2026 [1][7]. - The lawsuit alleges that Soleno made materially false and misleading statements regarding the safety and efficacy of DCCR, particularly concerning serious adverse reactions reported by patients [5][6]. Group 2: Stock Price Impact - Following the release of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27 per share, or 11.98%, closing at $68.09 on August 18, 2025 [3]. - After a patient death was disclosed on September 10, 2025, the stock price dropped by $13.49 per share, or 19.21%, closing at $56.72 on September 11, 2025 [3]. - On November 4, 2025, Soleno reported financial results indicating that the negative report had disrupted DCCR's launch, leading to a further decline of $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [4][5]. Group 3: Allegations Against Soleno - The lawsuit claims that Soleno's Phase 3 clinical trial for DCCR downplayed significant safety concerns, including issues related to excess fluid retention [6]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, leading to lower commercial viability and increased patient discontinuation rates [6].

Core Viewpoint - Soleno Therapeutics, Inc. is facing a class action lawsuit due to allegations of securities fraud related to its drug DCCR, with significant stock price declines following negative reports and disclosures [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2026, with a deadline to file a lead plaintiff motion by May 5, 2026 [1] - The lawsuit alleges that Soleno made materially false and misleading statements regarding the safety and efficacy of DCCR, failing to disclose significant safety concerns and risks associated with the drug [1] - Following the publication of a critical report by Scorpion Capital, Soleno's stock price dropped significantly, including a decline of $9.27 (11.98%) to $68.09 on August 18, 2025, and a further drop of $16.98 (26.59%) to $46.87 on November 5, 2025 [1] Group 2: Financial Impact - The report by Scorpion Capital raised concerns about the clinical trial conduct and safety of DCCR, leading to a disruption in its launch trajectory and a decrease in patient start forms [1] - The stock price fell by $13.49 (19.21%) to $56.72 after a patient death was disclosed on September 10, 2025, indicating a direct financial impact on investors [1] - The lawsuit claims that the company's positive statements about its business and prospects were misleading and lacked a reasonable basis, contributing to investor losses [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. on behalf of investors who acquired its common stock during the specified class period, alleging misleading statements and failure to disclose material adverse facts about the company's drug DCCR [1][6]. Group 1: Lawsuit Details - The lawsuit claims that Soleno made materially false and misleading statements regarding the safety and efficacy of its drug DCCR, particularly concerning significant safety concerns that were downplayed or concealed during clinical trials [6]. - Investors have until May 5, 2026, to file a lead plaintiff motion in this class action lawsuit [1][7]. Group 2: Stock Price Impact - Following the release of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27 per share, or 11.98%, closing at $68.09 on August 18, 2025 [2][3]. - After a patient death linked to DCCR was disclosed on September 10, 2025, the stock price dropped by $13.49 per share, or 19.21%, closing at $56.72 on September 11, 2025 [3]. - On November 4, 2025, after reporting third-quarter results that indicated disruption in DCCR's launch trajectory, the stock price fell by $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [4][5]. Group 3: Allegations Against the Company - The complaint alleges that Soleno failed to disclose that the Phase 3 clinical trial for DCCR had significant safety risks, including issues related to excess fluid retention, which posed greater risks than communicated [6]. - The lawsuit also claims that the commercial viability of DCCR was materially lower than represented, with undisclosed risks related to patient adoption, prescriber reluctance, and potential regulatory actions [6].

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) for securities fraud, alleging that the company made materially false statements and failed to disclose significant safety concerns regarding its drug DCCR during the class period from March 26, 2025, to November 4, 2026 [1] Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased SLNO common stock during the specified class period and have until May 5, 2026, to file a lead plaintiff motion [1] - The complaint alleges that Soleno's Phase 3 clinical trial for DCCR downplayed and concealed safety concerns, leading to materially greater risks than disclosed [1] - The lawsuit claims that positive statements made by Soleno regarding its business and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Stock Price Impact - Following the publication of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27 per share, or 11.98%, closing at $68.09 on August 18, 2025 [1] - After a patient death linked to DCCR was disclosed on September 10, 2025, the stock price dropped by $13.49 per share, or 19.21%, closing at $56.72 on September 11, 2025 [1] - On November 4, 2025, Soleno reported that the Scorpion Capital report had disrupted DCCR's launch, resulting in a further decline of $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [1] Group 3: Company Background - Soleno Therapeutics is focused on developing treatments for rare diseases, specifically targeting Prader-Willi syndrome with its drug DCCR [1] - The company has faced significant scrutiny regarding the safety and efficacy of its drug, which has impacted investor confidence and stock performance [1]

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) for securities fraud, affecting shareholders who acquired stock between March 26, 2025, and November 4, 2026, with a deadline for lead plaintiff motions set for May 5, 2026 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that Soleno made materially false and misleading statements and failed to disclose significant safety concerns regarding its drug DCCR, which is used to treat hyperphagia in individuals with Prader-Willi syndrome [1] - The complaint highlights that the Phase 3 clinical trial for DCCR downplayed safety risks, including issues related to excess fluid retention [1] - The lawsuit claims that the drug posed greater safety risks than disclosed, leading to lower commercial viability and increased patient discontinuation rates [1] Stock Price Impact - Following the release of a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell by $9.27, or 11.98%, closing at $68.09 on August 18, 2025 [1] - After a patient death was reported on September 10, 2025, the stock price dropped by $13.49, or 19.21%, to close at $56.72 on September 11, 2025 [1] - On November 4, 2025, Soleno's third-quarter financial results indicated that the negative report had disrupted DCCR's launch, causing the stock to decline by $16.98, or 26.59%, to close at $46.87 on November 5, 2025 [1]